S ystemic amyloidosis most commonly affects the heart and remains an underdiagnosed deadly disease. 1 Untreated cardiac amyloidosis is highly fatal with a median survival of less than 1 year for light chain (AL) amyloidosis and 4 years for wild-type transthyretin (ATTR) amyloidosis. 2, 3 With the emergence of several novel therapies, early diagnosis and treatment (particularly for AL amyloidosis) significantly improve survival. 4, 5 Thus, there is now a critical need to better understand the epidemiology of amyloidosis. No study has evaluated US amyloidosis mortality since 1986, to our knowledge. 6, 7 Because most amyloidosis mortality is caused by cardiac involvement, death certificate data may be a powerful study tool. We aimed to comprehensively analyze US trends in reported amyloidosis mortality from 1979 to 2015 and highlight potential regions of underdetection. Race and ethnicity were defined per the Office of Management and Budget as American Indian or Alaskan Native, Asian/ Pacific Islander, black or African American, white, Hispanic, or non-Hispanic. Amyloidosis mortality was analyzed by the state and county of the decedent's legal residence. This study did not require institutional review board approval as the analyses were performed using publicly available, deidentified data. Therefore, consent from study individuals also was not required.
Methods
Mortality from amyloidosis either as an underlying or contributing cause of death formed the primary end points. Data for 1979 to 1998 were only available for the underlying cause of death. Hence, any analyses including these data only report on amyloidosis as the underlying cause of death. All other analyses use multiple cause of death data for amyloidosis as a contributing cause of death for 1999 to 2015. For these data, amyloidosis may be listed as the underlying cause or 1 of up to 20 additional contributing causes of death. Comorbid conditions were estimated using the ICD-10 codes heart failure (I50.x), renal diseases (N00-N99), and multiple myeloma (C90.0). Centers listed on the Amyloidosis Foundation (http://amyloidosis.org/) or Amyloidosis Research Consortium (http://www.arci.org/) websites were considered amyloidosis referral centers.
Age-adjusted mortality rates per 1 000 000 with 95% confidence intervals were calculated. Linear regressions were used when appropriate (StataCorp 2015). Statistical significance was defined as a 2-sided P value less than .05. Tableau Public (version 10.3) software was used to display the geographic data. Interactive maps are available at https://goo.gl/RCdBV8. 
Results

Nationwide Amyloidosis Mortality Trends
Racial Differences in Amyloidosis Mortality
During 1999 to 2015, black men had the highest reported age-adjusted mortality rate at 12.36 per 1 000 000 (95% CI, 11.85-12.87), nearly twice the rate for white men (6.20 per 1 000 000 [95% CI, 6.09-6.31]) ( Figure 1 ). Black women had the second highest amyloidosis mortality rate (6.48 per 1 000 000 [95% CI, 6.19-6.77]).
Key Points
Question Are there regional differences in reported amyloidosis-related mortality in the United States?
Findings This cohort study found that amyloidosis-related mortality reported from US death certificates significantly increased from 1.77 to 3.96 per 1 000 000 between 1979 and 2015. The highest age-adjusted amyloidosis mortality rates were reported for black men and women; southern states reported the lowest US mortality rates despite having the highest proportions of black residents.
Meaning Geographic and racial variations in reported amyloidosis mortality, which is most commonly due to cardiac amyloidosis, suggest the potential for regional underdiagnosis.
Geographic Variation in Amyloidosis Mortality
Interstate differences were evident throughout the study period (eFigure 2A and B in the Supplement and interactive maps, available at https://goo.gl/RCdBV8) with most states reporting an increased mortality over time (eFigure 2C in the Supplement (Figure 2A) , reported the lowest mortality rates ( Figure 2B and C) .
We then assessed county data for amyloidosis as a contributing cause of death. The 5 counties with the highest 
Comorbidities in Individuals With Amyloidosis Mortality
Amyloidosis represents a range of protein misfolding diseases with multiorgan involvement and frequent delays in diagnosis. To identify associated comorbidities, we examined other reported contributing causes of death in 26 591 individuals with amyloidosis-related mortality (eFigure 3 in the Supplement). Amyloidosis was the underlying (ie, primary) cause of death in most cases (17 965 [67.4%]), followed by multiple myeloma (2575 [9. 66%]) and cardiovascular diseases (2539 [9.52%]). We examined comorbidities clinically associated with amyloidosis, including heart failure, renal disease, and multiple myeloma (eFigures 4 and 5 in the Supplement). Men and black individuals had a higher frequency of congestive heart failure compared with women and white individuals (eFigures 4A and 5A in the Supplement). No differences were observed for renal disease or multiple myeloma.
Discussion
We conducted an analysis of the largest and most racially diverse epidemiological data on reported US amyloidosis deaths to date. We discovered the following major findings: (1) the overall reported age-adjusted amyloidosis mortality rate has more than doubled from 1979 to 2015; (2) black men had the highest mortality rate that was 2-fold higher compared with other men; and (3) wide geographic variation in reported mortality raises the possibility of amyloidosis underdetection in many areas. Importantly, the mortality rates reported in this study reflect ascertainment of amyloidosis based on death certificates rather than necessarily indicating that the disease has become more lethal. The increasing death rates most likely represent increased disease recognition over time. For instance, counties with better access to amyloidosis centers reported the highest amyloidosis mortality rates. Areas around Rochester and Boston, home to the oldest US amyloidosis centers (Mayo Clinic and Boston University, respectively), had the first and third highest amyloidosis mortality rates. Of note, the Centers for Disease Control and Prevention's Wide-ranging ONline Data for Epidemiologic Research database records the county of residence of the decedent and thus reflects the mortality in the local population surrounding amyloidosis centers rather than mortality from patients referred to these centers. A similar inverse association was observed between amyloidosis mortality and distance to the National Amyloidosis Center in the United Kingdom. 8 These findings suggest an underdiagnosis of amyloidosis in locations with less access to specialized amyloidosis care. Moreover, we observed that black individuals were overrepresented in amyloidosis mortality, consistent with a previous study 6 and also reported for ATTR amyloidosis. 9 It could therefore be anticipated that areas with a high proportion of black residents (ie, southern states) would have higher amyloidosis mortality rates. Our contrary finding suggests that underdiagnosis is present. Wild-type transthyretin cardiomyopathy is responsible for a significant, underrecognized heart failure burden in black individuals and warrants targeted interventions. Approximately 3% to 4% of black individuals carry the amyloidogenic transthyretin gene mutation (valine-to-isoleucine substitution at codon 122), which confers higher lifetime risk of heart failure. 10 Furthermore, this type of variant ATTR cardiomyo- pathy was recently reported as the fourth leading cause of heart failure in individuals of African descent.
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Regions with underdiagnosis have options to improve. If clinically suspected, AL amyloidosis can now be diagnosed accurately at most medical centers using serum immunofixation and serum-free light chain measurements to identify abnormal paraproteins. 12 Cardiac amyloidosis can be suspected by echocardiography demonstrating a characteristic longitudinal strain pattern. 13 Advanced techniques, including cardiac magnetic resonance imaging with T1 mapping, technetium 99m pyrophosphate single-photon emission tomography, and fluorine 18-labeled amyloid imaging with positron emission tomography, can detect cardiac amyloidosis.
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Limitations
Despite its scope, our study has several limitations. The analyses are affected by the accuracy of ICD coding, including regional variations in death certificate reporting and race ascertainment. However, amyloidosis has well-defined clinicopathological characteristics, decreasing the chance of false positive diagnoses. ICD codes lack detail of the amyloidosis subtype, such as AL or ATTR amyloidosis. However, in this mortality study, the study individuals more likely represent severe cases (ie, cardiac amyloidosis). Indeed, cardiovascular disease was frequently listed as a cause of death on the amyloidosis death certificates. Despite these limitations, death certificates provide comprehensive information on an uncommon disease, such as amyloidosis, that is not otherwise feasible.
Conclusions
During 1979 to 2015, the reported US amyloidosis mortality increased and varied by sex, race/ethnicity, and geography. The clustering of mortality in regions with amyloidosis centers and the lack of higher reported mortality rates in states with a greater proportion of black residents support possible underdiagnosis of cardiac amyloidosis in these regions. Future studies are warranted to better understand these disparities in reported amyloidosis mortality. 
